{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T04:52:21Z","timestamp":1789447941845,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.jns.2020.116716","type":"journal-article","created":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T11:28:31Z","timestamp":1580988511000},"page":"116716","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Buprenorphine initiation to treat opioid use disorder in emergency rooms"],"prefix":"10.1016","volume":"411","author":[{"suffix":"Jr","given":"Stephen","family":"Jaeger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Fuehrlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2020.116716_bb0010","series-title":"Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration","article-title":"Key substance use and mental health indicators in the United States: results from the 2016 National Survey on Drug Use and Health","author":"Ahrnsbrak","year":"2017"},{"issue":"1","key":"10.1016\/j.jns.2020.116716_bb0015","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/jrh.12307","article-title":"Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5-year update","volume":"35","author":"Andrilla","year":"2018","journal-title":"J. Rural. Health"},{"key":"10.1016\/j.jns.2020.116716_bb0020","article-title":"Identification of substance-involved emergency department visits using data from the National Hospital Care Survey","volume":"115","author":"Brown","year":"2018","journal-title":"Nat. Health Stat. Rep."},{"issue":"11","key":"10.1016\/j.jns.2020.116716_bb0025","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1111\/add.13900","article-title":"Cost-effectiveness of emergency department-initiated treatment for opioid dependence","volume":"112","author":"Busch","year":"2017","journal-title":"Addiction"},{"key":"10.1016\/j.jns.2020.116716_bb0035","series-title":"Healthcare Systems and Services Practice","article-title":"Why we need bolder action to combat the opioid epidemic","author":"Charumilind","year":"2018"},{"key":"10.1016\/j.jns.2020.116716_bb0040","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.drugalcdep.2018.09.007","article-title":"Understanding the use of diverted buprenorphine","volume":"193","author":"Cicero","year":"2018","journal-title":"Drug Alcohol Depend."},{"issue":"Suppl 1(0 1)","key":"10.1016\/j.jns.2020.116716_bb0045","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1360-0443.2012.04040.x","article-title":"Neonatal neurobehavior effects following buprenorphine versus methadone exposure","volume":"107","author":"Coyle","year":"2012","journal-title":"Addiction"},{"key":"10.1016\/j.jns.2020.116716_bb0050","series-title":"The Facts about Buprenorphine for Treatment of Opioid Addiction","author":"Department of Health and Human Services USA","year":"2015"},{"issue":"16","key":"10.1016\/j.jns.2020.116716_bb0055","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1001\/jama.2015.3474","article-title":"Emergency department-initiated buprenorphine\/naloxone treatment for opioid dependence: a randomized clinical trial","volume":"313","author":"D\u2019Onofrio","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jns.2020.116716_bb0060","series-title":"U.S. Department of Health And Human Services Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality","article-title":"National estimates of drug-related emergency department visits (2013)","author":"Drug Abuse Warning Network","year":"2011"},{"issue":"4","key":"10.1016\/j.jns.2020.116716_bb0065","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.annemergmed.2018.04.007","article-title":"Identification, management, and transition of care for patients with opioid use disorder in the emergency department","volume":"72","author":"Duber","year":"2018","journal-title":"Ann. Emerg. Med."},{"issue":"2","key":"10.1016\/j.jns.2020.116716_bb0070","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jemermed.2019.03.029","article-title":"Retrospective review of a novel approach to buprenorphine induction in the emergency department","volume":"57","author":"Dunkley","year":"2019","journal-title":"J. Emerg. Med."},{"key":"10.1016\/j.jns.2020.116716_bb0075","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJMoa022164","article-title":"Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone","volume":"349","author":"Fudala","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2020.116716_bb0080","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.6373","article-title":"Characteristics of US counties with high opioid overdose mortality and low capacity to deliver medications for opioid use disorder","author":"Haffajee","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jns.2020.116716_bb0085","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0376-8716(95)01186-2","article-title":"A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence","volume":"40","author":"Johnson","year":"1995","journal-title":"Drug Alcohol Depend."},{"issue":"9358","key":"10.1016\/j.jns.2020.116716_bb0090","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0140-6736(03)12600-1","article-title":"1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomized, placebo-controlled trial","volume":"361","author":"Kakko","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2020.116716_bb0095","article-title":"Evaluation of an emergency department buprenorphine induction and medication-assisted treatment referral program","author":"Kaucher","year":"2019","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.jns.2020.116716_bb0100","series-title":"HCUP Statistical Brief #227","article-title":"Trends in emergency department visits, 2006\u20132014","author":"Moore","year":"2017"},{"issue":"12","key":"10.1016\/j.jns.2020.116716_bb0105","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1111\/add.12315","article-title":"Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine\/naloxone","volume":"108","author":"Rosenthal","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.jns.2020.116716_bb0110","series-title":"Kaplan & Sadocks Comprehensive Textbook of Psychiatry","year":"2017"},{"key":"10.1016\/j.jns.2020.116716_bb0115","author":"Scholl"},{"issue":"4","key":"10.1016\/j.jns.2020.116716_bb0120","first-page":"6","article-title":"The case for buprenorphine deregulation","volume":"26","author":"Walters","year":"2019","journal-title":"Fam. Pract. Manag."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X20300526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X20300526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:51:10Z","timestamp":1758383470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X20300526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":22,"alternative-id":["S0022510X20300526"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2020.116716","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Buprenorphine initiation to treat opioid use disorder in emergency rooms","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2020.116716","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116716"}}